Objective treatment response to endocrine therapy in metastatic prostate cancer.
A ten-year review of 198 patients with Stage D2 prostate cancer identified 13 patients (6.6%) who exhibited objective responses to hormonal treatment, as indicated by regression of a positive bone scan, CT scan, or chest x-ray film. Four patients had complete responses and 9 patients achieved partial responses as judged by the National Prostatic Cancer Project criteria. Median survival for those with objective treatment response has not yet been reached (> 44 months) compared with twenty-four months for the nonresponders (p = 0.00006). Although relatively uncommon, objective treatment response in Stage D2 prostate cancer is correlated with an improved prognosis.
Zaragoza
M R
MR
Department of Surgery, University of Michigan, Ann Arbor.
Grossman
H B
HB
D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
D004967:Estrogens; D005485:Flutamide